<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone with risk of overdose due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
